Stockreport

Immunome Says Phase 3 Trial for Varegacestat in Patients with Desmoid Tumors Meets Primary and Secondary Endpoints [Yahoo! Finance]

Immunome, Inc.  (IMNM) 
PDF Immunome (IMNM) said Monday that its global pivotal phase 3 trial evaluating varegacestat, an invest [Read more]